Rigosertib May Benefit Some Patients with Myelodysplastic Syndromes
Although there are currently no approved second-line therapies for high-risk MDS, researchers have discovered that rigosertib has the potential to benefit this population of patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: John Schieszer Tags: Myelodysplastic Syndromes News Source Type: news
More News: Cancer & Oncology | Myelodysplastic Syndrome